Targeting of CD122 enhances antitumor immunity by altering the tumor immune environment

Daniel O. Villarreal, Michael J. Allegrezza, Melissa A. Smith, Diana Chin, Leopoldo L. Luistro, Linda A. Snyder

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Mounting evidence demonstrates that CD8+CD122+ T cells have suppressive properties with the capacity to inhibit T cell responses. Therefore, these cells are rational targets for cancer immunotherapy. Here, we demonstrate that CD122 monoclonal antibody (mAb; aCD122) therapy significantly suppressed tumor growth and improved long-term survival in tumor-bearing mice. This therapeutic effect correlated with enhanced polyfunctional, cytolytic intratumoral CD8+ T cells and a decrease in granulocytic myeloid-derived suppressor cells (G-MDSCs). In addition, aCD122 treatment synergized with a vaccine to augment vaccine-induced antigen (Ag)-specific CD8+ T cell responses, reject established tumors and generate memory T cells. Furthermore, aCD122 mAb synergized with an anti-GITR (aGITR) mAb to confer significant control of tumor growth. These results suggest CD122 might be a promising target for cancer immunotherapy, either as a single agent or in combination with other forms of immunotherapy.

Original languageEnglish
Pages (from-to)109151-109160
Number of pages10
JournalOncotarget
Volume8
Issue number65
DOIs
StatePublished - 2017
Externally publishedYes

Keywords

  • CD122
  • CD8 T cells
  • GITR
  • Immunotherapy
  • Vaccines

Fingerprint

Dive into the research topics of 'Targeting of CD122 enhances antitumor immunity by altering the tumor immune environment'. Together they form a unique fingerprint.

Cite this